StreetAlpha.app
Home › Stocks › NTHI

Neonc Technologies Holdings, Inc. (NTHI)

$4.33
▼ −4.63%
LAST CLOSE · NOV 17

NeOnc Technologies develops drug candidates for brain cancers, including NEO100 and NEO212, which are still in clinical trials. It last closed at $4.33 on Nov 17, down 4.63% on the day. The average 12-month price target from 2 analysts is $17.50 (+304.2% from the last close), with a high of $20.00 and a low of $15.00.

AI Auto Pilots
Is NTHI in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$0
−100.0% vs a year ago
Net income
−$43.0M
EPS (diluted)
−$1.95
Valuation
Market cap
$124.9M
28.9M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$6.2M
At Sep 30
Shareholder equity
−$13.2M
Shares outstanding
28.9M
At Nov 5
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: $83K$83KFY2024FY2025: $40K$40KFY2025

From NTHI's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated NTHI in the past 90 days, not enough for a consensus
Average 12-month target
$17.50
▲ 304.2% upside

Based on 2 analysts who set a price target on NTHI in the past 90 days. The average target is $17.50, with a high of $20.00 and a low of $15.00, compared with the last close of $4.33.

Low $15.00Avg $17.50High $20.00
Blue marker: last close $4.33
Highest target$20.00
Average target$17.50
Lowest target$15.00
Latest rating changes
Roth CapitalInitiated
Sep 24Buy$20
BTIGReiterated
Sep 8Buy$15
Alliance Global PartnersInitiated
May 19Buy$13
Maxim GroupInitiated
May 18Buy$20
BTIGInitiated
Apr 24Buy$15
DateFirmActionRatingPrice target
Sep 24Roth CapitalInitiatedBuy$20
Sep 8BTIGReiteratedBuy$15
May 19Alliance Global PartnersInitiatedBuy$13
May 18Maxim GroupInitiatedBuy$20
Apr 24BTIGInitiatedBuy$15
Loading…

Technical Analysis

NTHI · as of the Nov 17 close · updated after every close
Bounce inside a longer downtrend, nearing overbought

The stock is 17% above its 20 day and 24% above its 50 day average. It is 19% below its 200 day average, so the longer trend is down. Momentum is strong (RSI 63), near overbought. The nearest support is the swing low (Jun 9) at $4.24, and the nearest resistance the Pivot at $4.52.

Short trendBullish
Long trendBearish
MomentumStrong
StretchNear overbought
VolatilityHigh, 11.2%/day
Key levels
$11.3852 week high+162.8%
$5.17200 day average+19.4%
$4.74Pivot R1+9.5%
$4.54Swing high (Jul 7)+4.8%
$4.52Pivot+4.4%
$4.33Last close
$4.24Swing low (Jun 9)−2.1%
$4.10Pivot S1−5.3%
$3.70100 day average−14.5%
$3.5820 day average−17.3%
$3.2950 day average−24.0%
$2.5052 week low−42.3%
Indicators
RSI (14)62.74Strong, overbought above 70Neutral
MACD0.40Above its signal lineBullish
Stochastic67.2Middle of its rangeNeutral
ADX (14)40.3Strong uptrend
Williams %R-43.9Oversold below −80, overbought above −20Neutral
CCI (20)94.9Oversold below −100, overbought above 100Neutral
Rate of change+41.0%Change over 10 sessionsBullish
ATR (14)$0.48Typical daily range, 11.2% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Below
What happened before, for NTHI

What happened before

See how NTHI did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in NTHI in the last 90 days.

Loading…

See today’s whale options flow across the market →

NTHI Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲11 buying vs 6 selling
  • ▲Held by funds +6.1 pts
  • ▲Funds holding +6
  • ▲Superinvestors: 1 added, 0 cut
  • ●Put/call not meaningful
Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding2721+28.6%
In funds' top 1000–
Held by funds17.1%11.0%+6.1 pts
New / increased6 / 51 / 11−8.3%
Reduced / sold out6 / 03 / 8−45.5%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See NTHI institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NTHI is in one of them and how their past NTHI trades turned out.

NTHI in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered NTHI in an article yet. Here's the latest on the wider market.

About Neonc Technologies Holdings

NeOnc Technologies develops drugs for cancers that start in the brain or spread there, including glioblastoma, meningioma and brain metastases from lung, breast and skin cancers. Its lead candidates are NEO100, a purified form of perillyl alcohol given by nasal spray, and NEO212, an oral drug that combines temozolomide with perillyl alcohol. The company has no approved products yet and is testing its candidates in trials with patients who have brain tumors. It is based in Calabasas, California.

Headquarters
Calabasas, CA